Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920972 · ClinicalTrials.gov registry record · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
A Phase 1 study of Hemoglobinopathies and Metabolic Disorders, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT00920972: Recruiting Phase 1 study of Hemoglobinopathies and Metabolic Disorders, sponsored by Washington University School of Medicine.
NCT00920972 is a Phase 1 study of Hemoglobinopathies and Metabolic Disorders that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 220 participants, below the 1,791-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00920972, a Phase 1 study of Hemoglobinopathies and Metabolic Disorders, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Primary Outcome
Engraftment is measured in myeloid and lymphoid lineage cells
Conditions Studied
Interventions
- DRUG Treatment Plan 1: Stratum 1
- DRUG Treatment Plan 2: Strata 2, 3, or 4
- DRUG GVHD Regimen A: UCB Recipients
- DRUG GVHD Regimen B: BM Recipients
Study Locations (20)
Florida
- Nemours Children's Health - Jacksonville
- University of Miami - Miami
- Miami Children's Hospital - Miami
- All Children's Hospital - St. Petersburg
Missouri
- Children's Mercy - Kansas City
- St. Louis University - St Louis
- Washington University School of Medicine (in St. Louis) - St Louis
North Carolina
- University of North Carolina - Chapel Hill
- Carolinas Medical Center - Charlotte
- Duke Children's Hospital - Durham
California
- Children's Hospital of Orange County - Orange
- University of California - San Diego
Arizona
- Phoenix Children's Hospital - Phoenix
Connecticut
- Yale School of Medicine - New Haven
District of Columbia
- George Washington University School of Medicine - Washington D.C.
Illinois
- Children's Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2001-12 |
| Est. Completion | 2031-12 |
| Phase | Phase 1 |
What NCT00920972 shows while recruiting
NCT00920972 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 1,791-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (88% lower).
The record links to 4 conditions, with Hemoglobinopathies appearing as the primary indexed condition, and to 4 interventions - of which Treatment Plan 1: Stratum 1 is the first listed.
NCT00920972 names 20 study sites across 12 states, led by Florida, Missouri, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00920972 about?
NCT00920972 is a clinical study titled "Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases". The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 ...
What is the current status of trial NCT00920972?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2001-12. Estimated completion is 2031-12.
What conditions does trial NCT00920972 study?
This clinical trial studies the following conditions: Hemoglobinopathies, Metabolic Disorders, Non-malignant Disorders, Hematologic, Immune, or Bone Marrow Disorders.
What interventions are being tested in trial NCT00920972?
The interventions under investigation include: Treatment Plan 1: Stratum 1 (DRUG), Treatment Plan 2: Strata 2, 3, or 4 (DRUG), GVHD Regimen A: UCB Recipients (DRUG), GVHD Regimen B: BM Recipients (DRUG).
Who is sponsoring clinical trial NCT00920972?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00920972 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemoglobinopathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00920972's enrollment target sits among peer trials
220 2nd of 17 the highest of 17 other Hemoglobinopathies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemoglobinopathies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
RECRUITING · Phase 1
-
A Blood Stem Cell Transplant for Sickle Cell Disease
ACTIVE NOT RECRUITING · Phase 1
-
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
ACTIVE NOT RECRUITING · Phase 1
-
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
ACTIVE NOT RECRUITING · Phase 1
-
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
COMPLETED · Phase 1
-
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
- NCT04421820 · 220 participants · Phase 1
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia